What laboratory and imaging studies constitute a complete plasma cell workup for suspected multiple myeloma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Complete Plasma Cell Workup for Suspected Multiple Myeloma

A complete plasma cell workup for suspected multiple myeloma requires comprehensive laboratory testing, bone marrow evaluation, cytogenetic analysis, and skeletal imaging—specifically whole-body low-dose CT or whole-body MRI, which have replaced conventional skeletal surveys. 1

Laboratory Testing

Serum Studies

  • Complete blood count with differential and peripheral blood smear (evaluate for rouleaux formation and circulating plasma cells)
  • Comprehensive metabolic panel including:
    • Calcium (hypercalcemia ≥11.5 mg/dL is a myeloma-defining event)
    • Creatinine (renal insufficiency ≥2 mg/dL is a myeloma-defining event)
    • Albumin (for International Staging System)
    • Liver function tests
    • Electrolytes
  • Serum protein electrophoresis (agarose gel or capillary zone electrophoresis preferred) with immunofixation
  • Nephelometric quantitation of immunoglobulins (IgG, IgA, IgM)—this is complementary to electrophoresis and particularly useful for detecting low levels of uninvolved immunoglobulins 1
  • Serum-free light chain assay with involved/uninvolved ratio (ratio ≥100 with involved FLC ≥100 mg/L is a myeloma-defining event) 1, 2, 3
  • Beta-2 microglobulin and LDH for prognostic staging 1

Urine Studies

  • 24-hour urine collection for protein electrophoresis and immunofixation—this cannot be replaced by random urine samples 1
  • Routine urinalysis
  • Quantification of monoclonal protein in 24-hour specimen (≥200 mg/24h contributes to myeloma-defining events when combined with serum FLC ratio ≥100) 2

Critical caveat: Both densitometer tracing and nephelometric quantitation should be performed as they are complementary. Nephelometric quantitation may overestimate monoclonal protein at high concentrations but provides accurate assessment of uninvolved immunoglobulins 1.

Bone Marrow Evaluation

  • Unilateral bone marrow aspirate and/or biopsy (≥10% clonal plasma cells required for diagnosis) 1, 2, 3
  • CD138 immunostaining should be used to accurately determine plasma cell percentage in biopsies 1
  • Clonality confirmation via immunoperoxidase staining or immunofluorescence for monoclonal immunoglobulin in plasma cell cytoplasm 1
  • Record the highest plasma cell percentage from either aspirate or biopsy (≥60% bone marrow plasma cells is a myeloma-defining event) 2, 3

Important: Trephine biopsy should be performed alongside aspirate to provide more reliable assessment of plasma cell infiltration and avoid need for repeat procedures if aspirate is inadequate 1.

Cytogenetic Analysis

Both conventional and molecular cytogenetics are mandatory 1:

Standard Metaphase Karyotyping

  • Despite low yield (~20%), separates hyperdiploid from non-hyperdiploid patients and captures uncommon abnormalities 1

FISH Analysis (preferably on sorted plasma cells)

Essential probes include:

  • del(17p) (high-risk)
  • t(4;14) (high-risk)
  • t(14;16) (high-risk)
  • t(14;20) (high-risk)
  • gain 1q (high-risk)
  • del(1p) (high-risk)
  • p53 mutation testing (high-risk) 2, 3

Risk stratification note: Two or more high-risk factors = double-hit myeloma; three or more = triple-hit myeloma, which significantly impacts treatment decisions 2, 3.

Imaging Studies

Primary Skeletal Assessment

Whole-body low-dose CT is now the recommended first-line imaging modality, having replaced conventional skeletal surveys due to superior sensitivity for detecting bone destruction 4, 5, 6. The skeletal survey (spine, pelvis, skull, humeri, femurs) is now considered outdated 1, 4.

Advanced Imaging (when indicated)

  • Whole-body MRI: More sensitive than CT for bone marrow involvement; >1 focal lesion ≥5mm is a myeloma-defining event even without bone destruction 2, 3, 4, 6
  • PET/CT with 18F-FDG: Comparable sensitivity to MRI; useful for assessing metabolic activity, extramedullary disease, and treatment response 7, 4, 6

Imaging algorithm: Start with whole-body low-dose CT for all suspected cases. Add whole-body MRI or PET/CT when CT shows no osteolysis but clinical suspicion remains high, or to evaluate bone marrow involvement and extramedullary disease 4, 6.

Diagnostic Criteria Summary

Multiple myeloma requires ≥10% clonal bone marrow plasma cells PLUS one or more myeloma-defining events (CRAB criteria or biomarkers):

  • C: Calcium ≥11.5 mg/dL
  • R: Renal insufficiency (creatinine ≥2 mg/dL)
  • A: Anemia (hemoglobin <10 g/dL or ≥2 g/dL below normal)
  • B: Bone lesions (lytic lesions, severe osteopenia, or pathologic fractures)
  • OR biomarkers: ≥60% bone marrow plasma cells, serum FLC ratio ≥100 (with involved FLC ≥100 mg/L), or >1 focal MRI lesion ≥5mm 1, 2, 3

Common pitfall: Do not diagnose myeloma based solely on M-protein level or plasma cell percentage without evidence of end-organ damage or myeloma-defining biomarkers—this would be smoldering myeloma, which does not require immediate treatment 1, 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.